Skip to main content

ANVISA's Digital Health Regulatory Framework

BR-unique

ANVISA has established a dedicated digital health regulatory framework through RDC 752/2022 (specific regulation for software as a medical device) and a series of public consultations and technical publications. The framework continues to evolve β€” with the core device regulation (RDC 751/2022) applying to all medical devices including SaMD, RDC 752/2022 providing specific requirements for software, and additional guidance being developed for AI/ML, mobile health, and connected devices.

ANVISA's approach to digital health​

ANVISA takes a risk-based, use-case-driven approach to digital health regulation:

  • If software is intended for a medical purpose (diagnosis, treatment, monitoring) β†’ it is a medical device and requires ANVISA registration.
  • If software is a general wellness or administrative tool β†’ it is not a medical device and does not require registration.
  • The intended purpose stated by the manufacturer determines which category applies.

Key regulatory instruments​

InstrumentContent
RDC 751/2022Core regulation β€” applies to all medical devices including SaMD
ANVISA Nota TΓ©cnica on SaMDANVISA's interpretation of the SaMD definition and classification
IMDRF SaMD N12Classification framework adopted by ANVISA
ANVISA digital health consultationOpen consultation on AI/ML, mobile health, and cybersecurity guidance

ANVISA's digital health team​

ANVISA has a dedicated digital health team within GPRODS that handles:

  • Classification inquiries for software and digital health products;
  • Technical review of SaMD registration dossiers; and
  • Development of guidance and regulatory framework for digital health.

Official resources​


Official sources

Verify all information against official ANVISA sources before making regulatory decisions.

Add the following sentence after the RDC 751/2022 entry in the Key regulatory instruments table:

RDC 752/2022 | Specific regulation for software as a medical device (SaMD) and digital health products β€” complements RDC 751/2022